| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 4 securities · passive | ||||||
|
Rapid Micro Biosystems, Inc.
13G/A
RPID · 75340L104
|
16.8% |
8/14/2026
Event 6/30/2026
|
||||
| Bain Capital Life Sciences Fund, L.P. | 16.8% | |||||
| BCIP Life Sciences Associates, LP | 1.7% | |||||
|
Pharvaris N.V.
13G/A
PHVS · N69605108
|
2.5% |
2/17/2026
Event 12/31/2025
|
||||
| Bain Capital Life Sciences Fund, L.P. | 2.5% | |||||
| BCIP Life Sciences Associates, LP | 0.3% | |||||
| Bain Capital Life Sciences Opportunities III, LP | 1.5% | |||||
|
X4 Pharmaceuticals, Inc.
13G/A
XFOR · 98420X202
|
7.4% |
2/17/2026
Event 12/31/2025
|
||||
| Bain Capital Life Sciences Fund, L.P. | 0% | |||||
| Bain Capital Life Sciences Fund II, L.P. | 0.1% | |||||
| BCIP Life Sciences Associates, LP | <0.1% | |||||
| BCLS II Investco, LP | 0.8% | |||||
| BCLS I Investco, LP | 0.1% | |||||
| BCLS II Equity Opportunities, LP | 7.4% | |||||
|
Annexon, Inc.
13G/A
ANNX · 03589W102
|
4.9% |
2/14/2025
Event 12/31/2024
|
||||
| BCLS I Investco, LP | 4.9% | |||||
| BCIP Life Sciences Associates, LP | 0% | |||||
| Bain Capital Life Sciences Fund, L.P. | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.